This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

5 Rocket Stocks to Buy Before Turkey Day

BALTIMORE (Stockpickr) -- Investors are getting heartburn this week, and it's not just from the turkey and mashed potatoes everyone will be eating on Thursday. Stocks have been in pullback mode for the last month and change, and that still has investors nervous about what's still to come for their portfolios this year.

>>5 Dividend Stocks Itching to Pay You More

But with Thanksgiving's shortened trading week upon us, weary investors could very well be due for a change -- historically, Thanksgiving offers a strong push for stocks. If nothing else, market reprieves on Thursday and half of Black Friday will offer investors a chance to sit back and mentally absorb the price action that we've been dealing with of late.

Even though we're looking at a shortened week, there are still market moves worth making. That's why we're taking a closer look at five new Rocket Stocks to start the week.

For the uninitiated, "Rocket Stocks" are our list of companies with short-term gain catalysts and longer-term growth potential. To find them, I run a weekly quantitative screen that seeks out stocks with a combination of analyst upgrades and positive earnings surprises to identify rising analyst expectations, a bullish signal for stocks in any market. After all, where analysts' expectations are increasing, institutional cash often follows.

>>> On Tuesday, November 20 at 6pm ET, TheStreet will host a Trade Credit Insurance webinar with Todd Lynady, Senior Underwriter for Zurich in North America and Mike DeLuca, Senior Partner of One Source. Register now.

Without further ado, here's a look at this week's Rocket Stocks.

AstraZeneca plc

We'll start off with biopharmaceutical firm AstraZeneca plc (AZN) -- and no, it's not just because the firm's heartburn drug, Nexium, could see a sales boost come Turkey Day. AstraZeneca is a $55 billion pharmaceutical stock with an impressive portfolio of brand name drugs and a truly worldwide presence. The firm generates less than 40% of sales in the United States, and it's been working hard to increase its exposure to high-growth emerging markets.

AstraZeneca's strong brands have had some impressive performance. Even drugs with recent generic competition have been able to boost their market share thanks to strong marketing campaigns, easing some worries about the patent cliff that AZN has looming on the horizon. Even so, patent dropoffs are still a big concern right now -- AstraZeneca is just coming off the expiration of blockbuster Lipitor's patent protection. To counter that, management has been very cost-conscious, cutting down on potential earnings drags further down the income statement.

Stock quotes in this article: ALZ, COST, TGT, AKAM, PCLN 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,407.19 -17.66 -0.11%
S&P 500 1,861.33 -0.98 -0.05%
NASDAQ 4,085.46 -0.7650 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs